Subsequent to this, we investigated whether administration of alirocumab or statin could alleviate NLRP3 activity, ultimately ameliorating lung fibrosis in TGF-β1 overexpressing transgenic mice. Here, NLRP3 is linked to pulmonary fibrosis.